Atlas Wealth’s Provectus Biopharmaceuticals PVCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.12K Hold
19,620
– – ﹤0.01% 176
2026
Q2
$1.36K Hold
19,620
– – ﹤0.01% 177
2026
Q1
$999 Buy
+19,620
New +$999 ﹤0.01% 115
2025
Q4
– Sell
-26,620
Closed -$2.37K – 116
2025
Q3
$2.37K Hold
26,620
– – ﹤0.01% 107
2025
Q2
$1.92K Hold
26,620
– – ﹤0.01% 108
2025
Q1
$2.66K Hold
26,620
– – ﹤0.01% 97
2024
Q4
$3.2K Hold
26,620
– – ﹤0.01% 94
2024
Q3
$2.61K Sell
26,620
-26,620
-50% -$2.61K ﹤0.01% 82
2024
Q2
$6.78K Buy
53,240
+26,620
+100% +$3.39K ﹤0.01% 234
2024
Q1
$4.87K Hold
26,620
– – ﹤0.01% 78
2023
Q4
$2.25K Hold
26,620
– – ﹤0.01% 78
2023
Q3
$2.25K Hold
26,620
– – ﹤0.01% 221
2023
Q2
$3.06K Hold
26,620
– – ﹤0.01% 229
2023
Q1
$4.39K Hold
26,620
– – ﹤0.01% 229
2022
Q4
$2.88K Buy
+26,620
New +$2.88K ﹤0.01% 128

Other funds holding PVCT

Atlas Wealth's PVCT Position: Q3 2026 in Review

Atlas Wealth held its Provectus Biopharmaceuticals (PVCT) position steady in Q3 2026 at 19,620 shares worth $1.12K. The position accounts for ﹤0.01% of the portfolio, ranked #176.

Atlas Wealth first reported a position in PVCT in Q4 2022 and has held it in 15 quarters since. The position peaked at $6.78K in Q2 2024. 3 funds tracked by Wall St. Rank hold PVCT as of Q3 2026.

  • Atlas Wealth held 19,620 shares of Provectus Biopharmaceuticals worth $1.12K as of Q3 2026.
  • Atlas Wealth left its Provectus Biopharmaceuticals share count unchanged in Q3 2026.
  • Provectus Biopharmaceuticals made up ﹤0.01% of Atlas Wealth's portfolio in Q3 2026, its #176 holding.
  • Atlas Wealth first reported a position in Provectus Biopharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • Atlas Wealth's Provectus Biopharmaceuticals position peaked at $6.78K in Q2 2024.
  • 3 funds tracked by Wall St. Rank held Provectus Biopharmaceuticals as of Q3 2026.

Based on Atlas Wealth's 13F filing for Q3 2026, filed 10 Nov 2026.